Switching antipsychotic medications: Not enough, too often, or just right?

American Journal of Psychiatry

Volumn 168, Issue 9, 2011, Pages 882-884

  Weiden, Peter J ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDITORIAL; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; METABOLIC DISORDER; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; DRUG SUBSTITUTION; HUMANS; HYPERCHOLESTEROLEMIA; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA;

EID: 80052444605     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11060958     Document Type: Editorial

References (14)

1. The President's New Freedom Commission on Mental Health: Achieving the Promise: Transforming Mental Health Care in America. 2003. www. mentalhealthcommission.gov/reports/Finalreport/toc-exec.html
2. Jenkins J.H., Carpenter-Song E.: The new paradigm of recovery from schizophrenia: Cultural conundrums of improvement without cure. Cult Med Psychiatry 2005; 29:379-413 (Pubitemid 44015099)
3. Colton C.W., Manderscheid R.W.: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 3:A42
4. Dean C.E., Thuras P.D.: Mortality and tardive dyskinesia: Long-term study using the US National Death Index. Br J Psychiatry 2009; 194:360-364
5. Gardos G., Cole J.O.: Maintenance antipsychotic therapy: Is the cure worse than the disease? Am J Psychiatry 1976; 133:32-36
6. Young A.S., Niv N., Cohen A.N., Kessler C., McNagny K.: The appropriateness of routine medication treatment for schizophrenia. Schizophr Bull 2010; 36:732-739
7. Gardos G.: Are antipsychotic drugs interchangeable? J Nerv Ment Dis 1974; 159:343-348
8. Essock S.M., Covell N.H., Davis S.M., Stroup T.S., Rosenheck R.A., Lieberman J.A.: Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006; 163:2090-2095 (Pubitemid 46114228)
9. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W.; Schizophrenia Patient Outcomes Research Team (PORT): The 2009 Schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36:71-93
10. Stroup T.S., McEvoy J.P., Ring K.D., Hamer R.H., LaVange L.M., Swartz M.S., Rosenheck R.A., Perkins D.O., Nussbaum A.M., Lieberman J.A.; Schizophrenia Trials Network: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry 2011; 168:947-956
11. Leslie D.L., Rosenheck R.A.: From conventional to atypical antipsychotics and back: Dynamic processes in the diffusion of new medications. Am J Psychiatry 2002; 159:1534-1540 (Pubitemid 35006734)
12. Newcomer J.W., Campos J.A., Marcus R.N., Breder C., Berman R.M., Kerselaers W., L'Italien G.J., Nys M., Carson W.H., McQuade R.D.: A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008; 69:1046-1056 (Pubitemid 352031586)
13. Weiden P.J., Newcomer J.W., Loebel A.D., Yang R., Lebovitz H.E.: Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008; 33:985-994 (Pubitemid 351367540)
14. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis C.E., Severe J., Hsiao J.K.; CATIE Investigators: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163:611-622 (Pubitemid 44464570)